source
- Recent heart-drug trials miss endpoints, raising doubts about AI-driven drug designTwo large clinical studies presented at the American Heart Association meeting this weekend failed to show any benefit for experimental heart‑attack and stroke therapies, underscoring the difficult…
- FDA opens investigation into Novartis' Zolgensma after cancer cases reportedThe U.S. Food and Drug Administration announced on Friday that it is opening a formal investigation into the gene-therapy product Zolgensma, marketed by Novartis for spinal muscular atrophy. The a…